Oestrogen-induced changes in lipoprotein metabolism

Role in prevention of atherosclerosis in the cholesterol-fed rabbit

P. Henriksson, M. Stamberger, M. Eriksson, M. Rudling, U. Diczfalusy, Lars Berglund, B. Angerlin

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Administration of moderate pharmacological doses of oestrogen to cholesterol-fed rabbits for 12 weeks resulted in a dramatically retarded development of arterial lesions as compared to non-oestrogen-treated, cholesterol-fed rabbits (7% vs. 47% aortal involvement). Oestrogen treatment was associated with a retarded increase in plasma cholesterol, and five times higher high density lipoprotein (HDL) to very low density lipoprotein (VLDL) cholesterol ratio. Expression of hepatic lipoprotein receptor activity, as detected by heparin-releasable binding of 125I-hypercholesterolaemic VLDL, was heavily suppressed by cholesterol feeding. Administration of oestrogen modulated this reponse and resulted in higher receptor expression. In accordance, oestrogen treatment resulted in a less prominent reduction of 125I-hypercholesterolaemic VLDL clearance in the cholesterol-fed rabbits. VLDL from both groups of cholesterol-fed animals stimulated cholesteryl ester synthesis in cultured macrophages to the same extent. Thus, in rabbits under a dietary cholesterol load, oestrogen counteracted hepatic lipoprotein receptor suppression, reduced plasma VLDL- and increased plasma HDL-cholesterol levels, and to a large extent abolished the development of atherosclerosis.

Original languageEnglish (US)
Pages (from-to)395-403
Number of pages9
JournalEuropean Journal of Clinical Investigation
Volume19
Issue number4
StatePublished - 1989
Externally publishedYes

Fingerprint

Metabolism
Lipoproteins
Atherosclerosis
Estrogens
VLDL Lipoproteins
Cholesterol
Rabbits
Lipoprotein Receptors
Plasmas
Dietary Cholesterol
VLDL Cholesterol
Cholesterol Esters
Macrophages
Liver
HDL Lipoproteins
HDL Cholesterol
Heparin
Animals
Pharmacology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Henriksson, P., Stamberger, M., Eriksson, M., Rudling, M., Diczfalusy, U., Berglund, L., & Angerlin, B. (1989). Oestrogen-induced changes in lipoprotein metabolism: Role in prevention of atherosclerosis in the cholesterol-fed rabbit. European Journal of Clinical Investigation, 19(4), 395-403.

Oestrogen-induced changes in lipoprotein metabolism : Role in prevention of atherosclerosis in the cholesterol-fed rabbit. / Henriksson, P.; Stamberger, M.; Eriksson, M.; Rudling, M.; Diczfalusy, U.; Berglund, Lars; Angerlin, B.

In: European Journal of Clinical Investigation, Vol. 19, No. 4, 1989, p. 395-403.

Research output: Contribution to journalArticle

Henriksson, P, Stamberger, M, Eriksson, M, Rudling, M, Diczfalusy, U, Berglund, L & Angerlin, B 1989, 'Oestrogen-induced changes in lipoprotein metabolism: Role in prevention of atherosclerosis in the cholesterol-fed rabbit', European Journal of Clinical Investigation, vol. 19, no. 4, pp. 395-403.
Henriksson, P. ; Stamberger, M. ; Eriksson, M. ; Rudling, M. ; Diczfalusy, U. ; Berglund, Lars ; Angerlin, B. / Oestrogen-induced changes in lipoprotein metabolism : Role in prevention of atherosclerosis in the cholesterol-fed rabbit. In: European Journal of Clinical Investigation. 1989 ; Vol. 19, No. 4. pp. 395-403.
@article{2acef5bc2a9648548499a77d4bba549e,
title = "Oestrogen-induced changes in lipoprotein metabolism: Role in prevention of atherosclerosis in the cholesterol-fed rabbit",
abstract = "Administration of moderate pharmacological doses of oestrogen to cholesterol-fed rabbits for 12 weeks resulted in a dramatically retarded development of arterial lesions as compared to non-oestrogen-treated, cholesterol-fed rabbits (7{\%} vs. 47{\%} aortal involvement). Oestrogen treatment was associated with a retarded increase in plasma cholesterol, and five times higher high density lipoprotein (HDL) to very low density lipoprotein (VLDL) cholesterol ratio. Expression of hepatic lipoprotein receptor activity, as detected by heparin-releasable binding of 125I-hypercholesterolaemic VLDL, was heavily suppressed by cholesterol feeding. Administration of oestrogen modulated this reponse and resulted in higher receptor expression. In accordance, oestrogen treatment resulted in a less prominent reduction of 125I-hypercholesterolaemic VLDL clearance in the cholesterol-fed rabbits. VLDL from both groups of cholesterol-fed animals stimulated cholesteryl ester synthesis in cultured macrophages to the same extent. Thus, in rabbits under a dietary cholesterol load, oestrogen counteracted hepatic lipoprotein receptor suppression, reduced plasma VLDL- and increased plasma HDL-cholesterol levels, and to a large extent abolished the development of atherosclerosis.",
author = "P. Henriksson and M. Stamberger and M. Eriksson and M. Rudling and U. Diczfalusy and Lars Berglund and B. Angerlin",
year = "1989",
language = "English (US)",
volume = "19",
pages = "395--403",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Oestrogen-induced changes in lipoprotein metabolism

T2 - Role in prevention of atherosclerosis in the cholesterol-fed rabbit

AU - Henriksson, P.

AU - Stamberger, M.

AU - Eriksson, M.

AU - Rudling, M.

AU - Diczfalusy, U.

AU - Berglund, Lars

AU - Angerlin, B.

PY - 1989

Y1 - 1989

N2 - Administration of moderate pharmacological doses of oestrogen to cholesterol-fed rabbits for 12 weeks resulted in a dramatically retarded development of arterial lesions as compared to non-oestrogen-treated, cholesterol-fed rabbits (7% vs. 47% aortal involvement). Oestrogen treatment was associated with a retarded increase in plasma cholesterol, and five times higher high density lipoprotein (HDL) to very low density lipoprotein (VLDL) cholesterol ratio. Expression of hepatic lipoprotein receptor activity, as detected by heparin-releasable binding of 125I-hypercholesterolaemic VLDL, was heavily suppressed by cholesterol feeding. Administration of oestrogen modulated this reponse and resulted in higher receptor expression. In accordance, oestrogen treatment resulted in a less prominent reduction of 125I-hypercholesterolaemic VLDL clearance in the cholesterol-fed rabbits. VLDL from both groups of cholesterol-fed animals stimulated cholesteryl ester synthesis in cultured macrophages to the same extent. Thus, in rabbits under a dietary cholesterol load, oestrogen counteracted hepatic lipoprotein receptor suppression, reduced plasma VLDL- and increased plasma HDL-cholesterol levels, and to a large extent abolished the development of atherosclerosis.

AB - Administration of moderate pharmacological doses of oestrogen to cholesterol-fed rabbits for 12 weeks resulted in a dramatically retarded development of arterial lesions as compared to non-oestrogen-treated, cholesterol-fed rabbits (7% vs. 47% aortal involvement). Oestrogen treatment was associated with a retarded increase in plasma cholesterol, and five times higher high density lipoprotein (HDL) to very low density lipoprotein (VLDL) cholesterol ratio. Expression of hepatic lipoprotein receptor activity, as detected by heparin-releasable binding of 125I-hypercholesterolaemic VLDL, was heavily suppressed by cholesterol feeding. Administration of oestrogen modulated this reponse and resulted in higher receptor expression. In accordance, oestrogen treatment resulted in a less prominent reduction of 125I-hypercholesterolaemic VLDL clearance in the cholesterol-fed rabbits. VLDL from both groups of cholesterol-fed animals stimulated cholesteryl ester synthesis in cultured macrophages to the same extent. Thus, in rabbits under a dietary cholesterol load, oestrogen counteracted hepatic lipoprotein receptor suppression, reduced plasma VLDL- and increased plasma HDL-cholesterol levels, and to a large extent abolished the development of atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0024339776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024339776&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 395

EP - 403

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 4

ER -